Iron and Heart Failure: Diagnosis, Therapies, and Future Directions

Area of Science:

• Cardiology
• Iron Metabolism
• Biochemistry

Background:

• Intravenous (IV) iron shows symptomatic benefit in heart failure (HF) patients with low serum iron, leading to treatment recommendations.
• However, the complex mechanisms of iron homeostasis in cardiomyocytes during health and disease remain poorly understood.
• Iron dysregulation in HF may be pathological or protective, and current serum markers don't reflect cellular iron status.

Purpose of the Study:

• To investigate the distinct and complex mechanisms of iron homeostasis in cardiomyocyte health and disease.
• To determine if observed iron dysregulation in heart failure is maladaptive or compensatory.
• To identify reliable markers of cellular iron status for better patient stratification.

Main Methods:

• Review of clinical trials and existing literature on iron metabolism in heart failure.
• Analysis of the limitations of current serum markers (ferritin, transferrin saturation) in reflecting cellular iron levels.
• Exploration of potential biomarkers for cellular and mitochondrial iron status.

Main Results:

• Clinical trials indicate symptomatic benefit of IV iron in HF patients with low serum iron.
• Current serum iron markers are insufficient to accurately assess cellular and mitochondrial iron levels in HF.
• Existing definitions for iron deficiency in HF may include patients who do not require IV iron.

Conclusions:

• Systemic and cellular iron metabolism in HF is complex and not fully understood.
• Reliable markers of cellular iron status are needed to differentiate HF patient subgroups.
• These markers could guide treatment towards iron chelation instead of IV iron, potentially improving outcomes and avoiding risks.